Diagnosis of prion diseases

Clinics in Laboratory Medicine

Volumn 23, Issue 1, 2003, Pages 109-128

  Kretzschmar, Hans A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; TAU PROTEIN;

CLINICAL EXAMINATION; CLINICAL FEATURE; ELECTROENCEPHALOGRAM; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRION DISEASE; PRIORITY JOURNAL; REVIEW; WESTERN BLOTTING;

EID: 0037366959     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00043-4     Document Type: Review

References (78)

1. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997;389:489-501.
2. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999;96:15137-42.
3. Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-88.
4. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
5. World Health Organization (WHO). Global surveillance. Diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation 1998. Available at http://www.who.int/csr/resources/publications/bse/GGTSPU-15484- 792688-DAT/whoemczdi989.pdf. Accessed February 3, 2003.
6. World Health Organization (WHO). The revision of the variant Creutzfeldt-Jakob (vCJD) case definition: report of a WHO consultation. Available at http://www.who.int/csr/resources/publications/bse/GGTSPU-15484- 869667-DAT/whocdscreph20015.pdf. Accessed February 3, 2003.
7. Steinhoff BJ, Räcker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996;53:162-6.
8. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-5.
9. Zerr I, Schulz-Schaeffer WJ, Giese A, et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol 2000;48:323-9.
10. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-7.
11. Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-8.
12. Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology 1996;199:793-8.
13. Zeidler M, Collie DA, Macleod MA, et al. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. Neurology 2001;56:282.
14. Coulthard A, Hall K, English PT, et al. Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease. Br J Radiol 1999;72:742-8.
15. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412-8.
16. Collie DA, Sellar RJ, Zeidler M, et al. Mri of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 2001;56:726-39.
17. Zerr I, Bodemer M, Räcker S, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345:1609-10.
18. Otto M, Stein H, Szudra A, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566-70.
19. Otto M, Wiltfang J, Tumni H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-3.
20. Otto M, Wiltfang J, Schütz E, et al. Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. BMJ 1998;316:577-82.
21. Miele G, Manson J, Clinton M. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Med 2001;7:361-4.
22. Windl O, Kretzschmar HA. Prion diseases. Contemp Neurol 2000;57:191-218.
23. Shibuya S, Higuchi J, Shin R-W, et al. Codon 219 lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1998;43:826-8.
24. Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular genetics of human prion diseases in Germany. Hum Genet 1999;105:244-52.
25. Deslys J-P, Jaegly A, d'Aignaux JH, et al. Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease. Lancet 1998;351:1251.
26. Kretzschmar HA, Ironside JW, DeArmond SJ, et al. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996;53:913-20.
27. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-33.
28. Ironside JW, Head MW, Bell JE, et al. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology 2000;37:1-9.
29. Hecker R, Taraboulos A, Scott M, et al. Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters. Genes Dev 1992;6:1213-28.
30. Taraboulos A, Jendroska K, Serban D, et al. Regional mapping of prion proteins in brain. Proc Natl Acad Sci USA 1992;89:7620-4.
31. Schulz-Schaeffer WJ, Tschöke S, Kranefuss N, et al. The paraffin-embedded tissue blot detects prp(sc) early in the incubation time in prion diseases. Am J Pathol 2000;156:51-6.
32. McBride PA, Schulz-Schaeffer WJ, Donaldson M, et al. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol 2001;75:9320-7.
33. Schulz-Schaeffer WJ, Fatzer R, Vandevelde M, et al. Detection of PrP(Sc) in subclinical BSE with the paraffin-embedded tissue (PET) blot. Arch Virol 2000;75(Suppl):173-80.
34. Bockman JM, Kingsbury DT, McKinley MP, et al. Creutzfeldt-Jakob disease prion proteins in human brains. N Engl J Med 1985;312:73-8.
35. Bendheim PE, Bockman JM, McKinley MP, et al. Scrapie and Creutzfeldt-Jakob disease prion proteins share physical properties and antigenic determinants. Proc Natl Acad Sci USA 1985;82:997-1001.
36. Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996;39:767-78.
37. Collinge J, Sidle KCL, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 1996;383:685-90.
38. Parchi P, Zou W, Wang W, et al. Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci USA 2000;97:10168-72.
39. Wadsworth JDF, Hill AF, Joiner S, et al. Strain-specific prion-protein conformation determined by metal ions. Nat Cell Biol 1999;1:55-9.
40. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001;24:519-50.
41. Parchi P, Capellari S, Chen SG, et al. Typing prion isoforms. Nature 1997;386:232-3.
42. Merz PA, Kascsak RJ, Rubenstein R, et al. Antisera to scrapie-associated fibril protein and prion protein decorate scrapie-associated fibrils. J Virol 1987;61:42-9.
43. Merz PA, Somerville RA, Wisniewski HM, et al. Scrapie-associated fibrils in Creutzfeldt-Jakob disease. Nature 1983;306:474-6.
44. Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983;35:349-58.
45. Hill AF, Zeidler M, Ironside J, et al. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997;349:99-100.
46. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-9.
47. Zeidler M, Knight R, Stewart G. et al. Diagnosis of Creutzfeldt-Jakob disease - routine tonsil biopsy for diagnosis of new variant Creutzfeldt-Jakob disease is not justified. BMJ 1999;318:538.
48. Pattison IH. Experiments with scrapie with special reference to the nature of the agent and the pathology of the disease. In: Gajdusek DC, Gibbs CJ, Alpers M. editors. Slow, latent, and temperate virus infections, NINDB monograph 2. Washington, DC: US Government Printing Office; 1965. p. 249-57.
49. Kimberlin RH, Walker CA. Pathogenesis of mouse scrapie: effect of route of inoculation on infectivity titres and dose-response curves. J Comp Pathol 1978;88(1):39-47.
50. Taylor DM, Dickinson AG, Fraser H, et al. Evidence that transmissible mink encephalopathy agent is biologically inactive in mice. Neuropathol Appl Neurobiol 1986;12:207-15.
51. Bosque PJ, Ryou C, Telling G, et al. Prions in skeletal muscle. Proc Natl Acad Sci USA 2002;99:3812-7.
52. SSC and EU. Opinion on TSE infectivity distribution in ruminant tissues. (State of Knowledge, December 2001). Adopted by the Scientific Stearing Committee at its Meeting of January 2002. Available at http://www.europa.eu.int/comm/food/fs/sc/ssc/GGTSPU-14810- 2579362-DAT/out241_en.pdf.
53. Brown P. The transmission of prion disease. Vertical transmission of prion disease. Hum Reprod 1994;9:1796-7.
54. Collinge J, Palmer MS, Sidle KCL, et al. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 1995;378:779-83.
55. Tateishi J, Sato Y, Ohta M. Creutzfeldt-Jakob disease in humans and laboratory animals. In: Zimmerman HM, editor. Progress in neuropathology, vol. 5. New York: Raven Press; 1983. p. 195-221.
56. Scott M, Foster D, Mirenda C, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 1989;59:847-57.
57. Telling GC, Scott M, Hsiao K, et al. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci USA 1994;91:9936-40.
58. Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995;83:79-90.
59. Hill A, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-50.
60. Hemmila I. Lanthanides as probes for time-resolved fluorometric immunoassays. Scand J Clin Lab Invest 1988;48:389-99.
61. MacGregor I, Hope J, Barnard G, et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999;77:88-96.
62. Barnard G, Helmick B, Madden S, et al. The measurement of prion protein in bovine brain tissue using differential extraction and DELFIA(R) as a diagnostic test for BSE. Luminescence 2000;15:357-62.
63. Schmerr MJ, Jenny A. A diagnostic test for scrapie-infected sheep using a capillary electrophoresis immunoassay with fluorescent-labeled peptides. Electrophoresis 1998;19:409-14.
64. Schmerr MJ, Jenny AL, Bulgin MS, et al. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A 1999;853:207-14.
65. Brown P. Creutzfeldt-Jakob disease: blood infectivity and screening tests. Semin Hematol 2001;38:2-6.
66. Kocisko DA, Come JH, Priola SA, et al. Cell-free formation of protease-resistant prion protein. Nature 1994;370:471-3.
67. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001;411:810-3.
68. Horiuchi M, Caughey B. Prion protein interconversions and the transmissible spongiform encephalopathies. Structure Fold Des 1999;7:R231-R40.
69. Saborio GP, Soto C, Kascsak RJ, et al. Cell-lysate conversion of prion protein into its protease- resistant isoform suggests the participation of a cellular chaperone. Biochem Biophys Res Commun 1999;258:470-5.
70. Shaked GM, Shaked Y, Kariv-Inbal Z, et al. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001;276:31479-82.
71. Safar J, Wille H, Itri V, et al. Eight prion strains have PrPsc molecules with different conformations. Nat Med 1998;4:1157-65.
72. Huang Z, Prusiner SB, Cohen FE. Scrapie prions: a three-dimensional model of an infectious fragment. Folding & Design 1995;1:13-21.
73. Eigen M, Rigler R. Sorting single molecules: application to diagnostics and evolutionary biotechnology. Proc Natl Acad Sci USA 1994;91:5740-7.
74. Bieschke J, Giese A, Schulz-Schaeffer W, et al. Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 2000;97:5468-73.
75. Brown P, Gibbs CJ, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513-29.
76. Beekes M, Baldauf E, Diringer H. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. J Gen Virol 1996;77:1925-34.
77. Meyer RK, McKinley MP, Bowman KA, et al. Separation and properties of cellular and scrapie prion protein. Proc Natl Acad Sci USA 1986;83:2310-4.
78. Bolton DC, Bendheim PE, Marmorstein AD, et al. Isolation and structural studies of the intact scrapie agent protein. Arch Biochem Biophys 1987;258:579-90.